Browse > Article

Antiviral Effect of a Combination Therapy of Amantadine/Biphenyl Dimethyl Dicarboxylate in HepG2 2.2.15  

Joo, Seong-Soo (College of Pharmacy, Chung-Ang University)
Won, Tae-Joon (College of Pharmacy, Chung-Ang University)
Lee, Yong-Jin (College of Pharmacy, Chung-Ang University)
Hwang, Kwang-Woo (College of Pharmacy, Chung-Ang University)
Lee, Do-Ik (College of Pharmacy, Chung-Ang University)
Publication Information
YAKHAK HOEJI / v.49, no.2, 2005 , pp. 151-155 More about this Journal
Abstract
For decades, the demand for new antiviral strategies, especially in hepatitis, has increased markedly due to its devastating pathogenic outcome, In the present study, we examin ed the antiviral effect of the combination of amantadine and biphenyl dimethyl dicarboxylate (DDB) in HepG2 2.2.15, which is transfected with HBV DNA. The study demonstrated that the combination not the single treatment may have an anti-HBV effect through a synergism of antiviral, anti-inflammatory and cytoprotective activities in STAT1 ${\alpha}$, 6-16 gene, and pro-inflammatory components such as nitric oxide and IL-1${\beta}$ expression. In addition, hepatitis B surface and core gene expression were examined as a final end point for the anti-HBV activities, which was also significantly suppressed comparing to normal control (p<0.01).
Keywords
amantadine; DDB; hepatitis B surface gene; hepatitis B core gene; HepG2 2.2.15;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wright, M., Main, J. and Thomas, H. C. : Drug-resistant viral hepatitis. J. Infection. 41, 1 (2000)   DOI   ScienceOn
2 Witcher, J. W, Bouldinot, F. D., Baldwin, B. H., Ascenzi, M. A., Tennant, B. C., Du, J. F. and Chu, C. K : Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl) uracil in woodchucks. Antimicrob. Agents Chemother. 41, 2184 (1997)
3 Huber, R, Hockenjos, B. and Blum, H. E. : DDB treatment of patients with chronic hepatitis. Hepatology 39, 1732 (2004)   DOI   ScienceOn
4 Khabar, K. S. A., al-Haj, L., al-Zoghaibi, F., Marie, M., Dhalla, M., Polyak, S. J. and Williams, B. R. G. : Expressed gene cluster associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J. Mol. Biol. 342, 833 (2004)   DOI   ScienceOn
5 Joo, S. S., Won, T. J. and Lee, D. I. : Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch. Pharm. Res. 27, 954 (2004)   DOI   ScienceOn
6 Kang, K. W., Kim, Y. G., Kim, C. W. and Kim, S. G. : The antifibrogenic effect of a pharmaceutical composition of [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) Arch. Pharm. Res. 25, 655 (2002).   DOI   ScienceOn
7 Bose, S., Kar, N., Maitra, R, DiDonato, J. A. and Banerjee, A. K. : Temporal activation of NF-$_{\kappa}B$ regulates an interferonindependent innate antiviral response against cytoplasmic RNA viruses. Proc. Natl. Acad. Sci. USA 100, 10890 (2003)
8 Heathcote, E., Jeffers, L. and Wright, T. : Loss of serum HBV DNA and HBeAg seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 28, A620 (1998)   DOI   ScienceOn
9 Yamanaka, G., Wilson, T., Innaimo, S., Bisacchi, G. S., Egli, P., Rinehart, J. K, Zahler, R and Colonno, R. J. : Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43, 190 (1999)
10 Lee, W. M. : Hepatitis B virus infection. N. Engl. J. Med. 337, 1733 (1997)   DOI   ScienceOn
11 Kim, J. H., Mun, Y. J., Chun, H. J., Jeon, K. S., Kim, Y. O. and Woo, W. H. : Effect of biphenyl dimethyl dicarboxylate on the humoral immunosuppression by ethanol. Int. J. Immunother. 22, 906 (2000)
12 Lai, C. L., Ratziu, V., Yuen, M .-F. and Poynard, T. : Viral hepatitis B. Lancet 362, 2089 (2003)   DOI   ScienceOn
13 Biermer, M., Puro, R. and Schneider, R. J. : Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves distribution of capsid integrity through activation of NF-$_{\kappa}B$. J. Virol. 77, 4033 (2003)
14 Wang, C., Takeuchi, K, Pinto, L. and Lamb, R. A. : Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67, 585 (1993)
15 Hoofnagle, J. H. : Hepatitis C: The clinical spectrum of disease. Hepatology 26, 15S (1997)   DOI   PUBMED   ScienceOn
16 Oxford, J. S., Blasingam, B. S., Mann, A., Novelli, P. and Lambkin, R. : Treatment of epidemic and pandemic influenza with neuraminidase and M2 protein channel inhibitors. Clin. Midrobiol. Infect. 9, 1 (2003)   DOI   ScienceOn
17 Ramana, C. V., Gil, M. P., Schreiber; R. D. and Stark, G. R : STAT1-dependent and -independent pathways in IFN-${\gamma}$-dependent signaling. Trends Immunol. 23, 96 (2002)   DOI   ScienceOn
18 Guidotti, L. G., McClary, H., Loudis, J. M. and Chisari, F. V. : Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J. Exp. Med. 191, 1247 (2000)   DOI   ScienceOn
19 Fisher, K., Cheng, Y. and Tyrrell, D. : The mutation in duck hepatitis B polymerase which confers resistance to lamivudine (${\beta}$-L(-)-thiacytidine, 3TC) also confers cross-resistance to ${\beta}$-L-dideoxy-5-fluorocytidine. Hepaiology 24, A246 (1996)
20 Tian, Z., Shen, X., Feng, H. and Gao, B. : IL-1${\beta}$ attenuates IFN-${\alpha}\;{\beta}$-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J. Immunol. 165, 3959 (2000)   DOI